Seven Bridges Advisors LLC cut its stake in Teva Pharm Adr (NYSE:TEVA) by 33.3% during the third quarter, Holdings Channel reports. The fund owned 15,008 shares of the company’s stock after selling 7,495 shares during the period. Seven Bridges Advisors LLC’s holdings in Teva Pharm Adr were worth $691,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Greatmark Investment Partners Inc. increased its position in Teva Pharm Adr by 0.4% in the third quarter. Greatmark Investment Partners Inc. now owns 125,478 shares of the company’s stock valued at $5,773,000 after buying an additional 495 shares during the last quarter. Quantbot Technologies LP increased its position in Teva Pharm Adr by 16.3% in the third quarter. Quantbot Technologies LP now owns 103,544 shares of the company’s stock valued at $4,764,000 after buying an additional 14,486 shares during the last quarter. Advisors Asset Management Inc. increased its position in Teva Pharm Adr by 3.7% in the third quarter. Advisors Asset Management Inc. now owns 25,171 shares of the company’s stock valued at $1,158,000 after buying an additional 889 shares during the last quarter. APG Asset Management N.V. purchased a new position in Teva Pharm Adr during the third quarter valued at approximately $4,499,000. Finally, State of Wisconsin Investment Board purchased a new position in Teva Pharm Adr during the third quarter valued at approximately $31,535,000. Hedge funds and other institutional investors own 54.53% of the company’s stock.
Shares of Teva Pharm Adr (NYSE:TEVA) traded down 1.85% on Thursday, hitting $33.47. The stock had a trading volume of 7,498,760 shares. Teva Pharm Adr has a one year low of $33.46 and a one year high of $64.31. The stock has a market cap of $33.97 billion, a PE ratio of 19.47 and a beta of 0.65. The company’s 50 day moving average is $36.11 and its 200 day moving average is $45.20.
Teva Pharm Adr (NYSE:TEVA) last announced its earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.02. Teva Pharm Adr had a net margin of 8.81% and a return on equity of 16.75%. The business earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the firm earned $1.35 earnings per share. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. Equities research analysts predict that Teva Pharm Adr will post $5.12 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th were paid a dividend of $0.34 per share. The ex-dividend date was Thursday, December 1st. This represents a $1.36 annualized dividend and a dividend yield of 4.06%. Teva Pharm Adr’s dividend payout ratio (DPR) is 67.44%.
TEVA has been the topic of several research reports. Leerink Swann restated a “buy” rating on shares of Teva Pharm Adr in a report on Friday, September 23rd. Mizuho restated a “buy” rating and set a $64.00 price objective on shares of Teva Pharm Adr in a report on Monday, September 26th. OTR Global initiated coverage on Teva Pharm Adr in a report on Thursday, September 29th. They issued a “positive” rating on the stock. Bank of America Corp. set a $72.00 price target on Teva Pharm Adr and gave the company a “buy” rating in a report on Saturday, October 1st. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Teva Pharm Adr in a report on Monday, October 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Teva Pharm Adr has a consensus rating of “Buy” and a consensus target price of $56.38.
About Teva Pharm Adr
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharm Adr (NYSE:TEVA).